SURI

JK:SURI Indonesia Medical Instruments & Supplies
Market Cap
$38.25
Rp622.31K IDR
Market Cap Rank
#50469 Global
#924 in Indonesia
Share Price
Rp66.00
Change (1 day)
+11.86%
52-Week Range
Rp59.00 - Rp151.00
All Time High
Rp151.00
About

PT Maja Agung Latexindo Tbk engages in the manufacture and sale of gloves in Indonesia. The company offers examination gloves, industrial gloves, and specialty gloves; and concentrated latex. It serves the medical and healthcare, industrial, and beauty care industries. The company also exports its products. PT Maja Agung Latexindo Tbk was founded in 1988 and is based in Deli Serdang, Indonesia.

SURI (SURI) - Net Assets

Latest net assets as of June 2025: Rp344.55 Billion IDR

Based on the latest financial reports, SURI (SURI) has net assets worth Rp344.55 Billion IDR as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp394.35 Billion) and total liabilities (Rp49.80 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Rp344.55 Billion
% of Total Assets 87.37%
Annual Growth Rate 50.55%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 95.77

SURI - Net Assets Trend (2020–2024)

This chart illustrates how SURI's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for SURI (2020–2024)

The table below shows the annual net assets of SURI from 2020 to 2024.

Year Net Assets Change
2024-12-31 Rp343.17 Billion -0.98%
2023-12-31 Rp346.57 Billion +235.04%
2022-12-31 Rp103.44 Billion +10.92%
2021-12-31 Rp93.26 Billion +39.59%
2020-12-31 Rp66.81 Billion --

Equity Component Analysis

This analysis shows how different components contribute to SURI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 77.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings Rp7.46 Billion 2.17%
Common Stock Rp126.69 Billion 36.92%
Other Components Rp209.02 Billion 60.91%
Total Equity Rp343.17 Billion 100.00%

SURI Competitors by Market Cap

The table below lists competitors of SURI ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in SURI's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 346,572,800,000 to 343,168,679,000, a change of -3,404,121,000 (-1.0%).
  • Net loss of 3,873,515,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Rp-3.87 Billion -1.13%
Other Changes Rp469.39 Million +0.14%
Total Change Rp- -0.98%

Book Value vs Market Value Analysis

This analysis compares SURI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.90x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 6.26x to 0.90x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-12-31 Rp10.55 Rp66.00 x
2021-12-31 Rp14.72 Rp66.00 x
2022-12-31 Rp16.33 Rp66.00 x
2023-12-31 Rp74.33 Rp66.00 x
2024-12-31 Rp73.60 Rp66.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently SURI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -1.13%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -3.32%
  • • Asset Turnover: 0.29x
  • • Equity Multiplier: 1.16x
  • Recent ROE (-1.13%) is below the historical average (16.36%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2020 43.14% 9.20% 1.42x 3.31x Rp22.14 Billion
2021 28.34% 7.82% 1.56x 2.32x Rp17.10 Billion
2022 9.89% 10.96% 0.50x 1.82x Rp-118.08 Million
2023 1.58% 6.69% 0.20x 1.18x Rp-29.19 Billion
2024 -1.13% -3.32% 0.29x 1.16x Rp-38.19 Billion

Industry Comparison

This section compares SURI's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $406,922,931,319
  • Average return on equity (ROE) among peers: 62.87%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
SURI (SURI) Rp344.55 Billion 43.14% 0.14x $39.35
Mark Dynamics Indonesia Tbk PT (MARK) $237.74 Billion 34.45% 0.34x $36.64 Million
PT Hetzer Medical Indonesia Tb (MEDS) $32.46 Billion 82.03% 0.54x $2.39 Million
Jayamas Medica Industri (OMED) $950.57 Billion 72.12% 0.49x $62.25 Million